Live Breaking News & Updates on உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம்|Page 3

Stay updated with breaking news from உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Increased access to testing, treatment has reduced hepatitis C in low- and middle-income countries

Increased access to testing, treatment has reduced hepatitis C in low- and middle-income countries
Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment. Some achieved a 20-fold increase in the number of people treated with safe and effective direct-acting retroviral drugs between 2015 and 2018, according to the
Global progress report on accelerating access to hepatitis C diagnostics and treatment, released by WHO today.
A drop in prices underpins this success
Low- and middle-income countries can now aim to achieve a price as low as US$ 60 per patient for a 12-week course of treatment with WHO-prequalified generic sofosbuvir and daclatasvir. Prices offered by suppliers of WHO-prequalified HCV rapid diagnostic tests ranged between US$ 1 and US$ 8 per test. ....

Minghui Ren , Mariangela Simao , Meg Doherty , Emily Henderson , Department Of Global , Health Coverage Communicable , Global Health Sector Strategy On Viral Hepatitis , Health Products , Global Health Sector Strategy , Viral Hepatitis , Assistant Director General Access , Hepatitis C , மெக் டோவர்டீ , எமிலி ஹென்டர்சன் , துறை ஆஃப் உலகளாவிய , ஆரோக்கியம் பாதுகாப்பு தொடர்பு கொள்ளக்கூடியது , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் ஆன் வைரஸ் ஹெபடைடிஸ் , ஆரோக்கியம் ப்ராடக்ட்ஸ் , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் , வைரஸ் ஹெபடைடிஸ் , உதவியாளர் இயக்குனர் ஜநரல் நுழைவு , சர்வதேச பரவல் ,

Accelerating access to hepatitis C diagnostics and treatment: Overcoming barriers in low- and middle-income countries - Global progress report 2020 - World

Accelerating access to hepatitis C diagnostics and treatment: Overcoming barriers in low- and middle-income countries - Global progress report 2020
Format
The 2020 global report on access to hepatitis C diagnostics and treatment is being published at
an unprecedented time for global health. The data presented in this report were collected in 2019. Since then, the coronavirus disease (COVID)-19 pandemic has spread to countries and populations worldwide, resulting in 79 million infections and about 1.7 million deaths by end December 2020. Many countries are already facing major disruptions to essential health services. They risk a reversal of decades of progress in health and development. The pandemic is a strong reminder that we need to continue to invest in building resilient health systems for universal health coverage and respond to emergencies. It is also an urgent call to maintain the momentum towards achieving the goals of the 2030 Agenda for Sustainable Developm ....

World Health Organization , Al Qahirah , United States , Global Fund , Agenda For Sustainable Development , Global Health Sector Strategy On Viral Hepatitis , Global Health Sector Strategy , Viral Hepatitis , Saharan African , Medicines Patent Pool , Accelerated Registration , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , ஒன்றுபட்டது மாநிலங்களில் , உலகளாவிய நிதி , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் ஆன் வைரஸ் ஹெபடைடிஸ் , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் , வைரஸ் ஹெபடைடிஸ் , மருந்துகள் காப்புரிமை பூல் , முடுக்கப்பட்ட பதிவு ,

WHO on progress in access to hepatitis C diagnostics and treatment

Date Time
WHO on progress in access to hepatitis C diagnostics and treatment
Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment. Some achieved a 20-fold increase in the number of people treated with safe and effective direct-acting retroviral drugs between 2015 and 2018, according to the Global progress report on accelerating access to hepatitis C diagnostics and treatment, released by WHO today.
A drop in prices underpins this success
Low- and middle-income countries can now aim to achieve a price as low as US$ 60 per patient for a 12-week course of treatment with WHO-prequalified generic sofosbuvir and daclatasvir. Prices offered by suppliers of WHO-prequalified HCV rapid diagnostic tests ranged between US$ 1 and US$ 8 per test. ....

Minghui Ren , Mariangela Simao , Meg Doherty , Department Of Global , Health Coverage Communicable , Global Health Sector Strategy On Viral Hepatitis , Health Products , Global Health Sector Strategy , Viral Hepatitis , Assistant Director General Access , மெக் டோவர்டீ , துறை ஆஃப் உலகளாவிய , ஆரோக்கியம் பாதுகாப்பு தொடர்பு கொள்ளக்கூடியது , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் ஆன் வைரஸ் ஹெபடைடிஸ் , ஆரோக்கியம் ப்ராடக்ட்ஸ் , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் , வைரஸ் ஹெபடைடிஸ் , உதவியாளர் இயக்குனர் ஜநரல் நுழைவு ,

WHO highlights progress in accelerating access to hepatitis C diagnostics and treatment in low- and middle-income countries

WHO highlights progress in accelerating access to hepatitis C diagnostics and treatment in low- and middle-income countries
WHO / Blink Media - Martyn Aim
©
Credits
WHO highlights progress in accelerating access to hepatitis C diagnostics and treatment in low- and middle-income countries
27 January 2021
Reading time:
Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment. Some achieved a 20-fold increase in the number of people treated with safe and effective direct-acting retroviral drugs
between 2015 and 2018, according to the
A drop in prices underpins this success
Low- and middle-income countries can now aim to achieve a price as low as US$ 60 per patient for a 12-week course of treatment with WHO-prequalified generic sofosbuvir and daclatasvir. Prices offered by suppliers of WHO-prequalified HCV rapid diagnostic ....

Minghui Ren , Mariangela Simao , Meg Doherty , Department Of Global , Health Coverage Communicable , Global Health Sector Strategy On Viral Hepatitis , Health Products , Global Health Sector Strategy , Viral Hepatitis , Assistant Director General Access , மெக் டோவர்டீ , துறை ஆஃப் உலகளாவிய , ஆரோக்கியம் பாதுகாப்பு தொடர்பு கொள்ளக்கூடியது , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் ஆன் வைரஸ் ஹெபடைடிஸ் , ஆரோக்கியம் ப்ராடக்ட்ஸ் , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் , வைரஸ் ஹெபடைடிஸ் , உதவியாளர் இயக்குனர் ஜநரல் நுழைவு ,